image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - JP
$ 13.62
0.368 %
$ 43.2 B
Market Cap
23.08
P/E
1. INTRINSIC VALUE

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc.[ Read More ]

The intrinsic value of one TAK stock under the base case scenario is HIDDEN Compared to the current market price of 13.6 USD, Takeda Pharmaceutical Company Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TAK

image
FINANCIALS
4.26 T REVENUE
5.87%
214 B OPERATING INCOME
-56.36%
144 B NET INCOME
-54.56%
640 B OPERATING CASH FLOW
-34.47%
-464 B INVESTING CASH FLOW
23.59%
-354 B FINANCING CASH FLOW
50.02%
1.18 T REVENUE
-2.65%
184 B OPERATING INCOME
10.77%
92.1 B NET INCOME
-3.35%
281 B OPERATING CASH FLOW
76.29%
-75.1 B INVESTING CASH FLOW
52.05%
-110 B FINANCING CASH FLOW
-34.78%
Balance Sheet Decomposition Takeda Pharmaceutical Company Limited
image
Current Assets 2.56 T
Cash & Short-Term Investments 458 B
Receivables 698 B
Other Current Assets 1.4 T
Non-Current Assets 12.6 T
Long-Term Investments 89.8 B
PP&E 1.99 T
Other Non-Current Assets 10.5 T
Current Liabilities 2.31 T
Accounts Payable 320 B
Short-Term Debt 500 B
Other Current Liabilities 1.49 T
Non-Current Liabilities 5.52 T
Long-Term Debt 5.03 T
Other Non-Current Liabilities 492 B
EFFICIENCY
Earnings Waterfall Takeda Pharmaceutical Company Limited
image
Revenue 4.26 T
Cost Of Revenue 1.94 T
Gross Profit 2.32 T
Operating Expenses 2.62 T
Operating Income 214 B
Other Expenses 70 B
Net Income 144 B
RATIOS
54.44% GROSS MARGIN
54.44%
5.02% OPERATING MARGIN
5.02%
3.38% NET MARGIN
3.38%
1.98% ROE
1.98%
0.95% ROA
0.95%
4.80% ROIC
4.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Takeda Pharmaceutical Company Limited
image
Net Income 144 B
Depreciation & Amortization 728 B
Capital Expenditures -481 B
Stock-Based Compensation 70.9 B
Change in Working Capital -256 B
Others -24.7 B
Free Cash Flow 160 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Takeda Pharmaceutical Company Limited
image
TAK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.333 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Takeda Pharmaceutical Company Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies, and more. youtube.com - 1 day ago
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Ramona Sequeira - President, Global Portfolio Julie Kim - President, U.S. Business Unit Giles Platford - President, PDT Business Unit Teresa Bitetti - President, Global Oncology Business Unit Conference Call Participants Steve Barker - Jefferies Mike Nedelcovych - TD Cowen Tony Ren - Macquarie Miki Sogi - Bernstein Christopher O'Reilly Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I'm the master of ceremony, Head of IR. seekingalpha.com - 2 weeks ago
Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs. reuters.com - 2 weeks ago
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions. T. businesswire.com - 2 weeks ago
Takeda Pharmaceuticals: An Interesting Option For Income Investors Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins. seekingalpha.com - 1 month ago
TAK or CTLT: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? zacks.com - 1 month ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon. businesswire.com - 1 month ago
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chem. businesswire.com - 1 month ago
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering h. businesswire.com - 1 month ago
TAK vs. STVN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? zacks.com - 2 months ago
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 months ago
8. Profile Summary

Takeda Pharmaceutical Company Limited TAK

image
COUNTRY JP
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 43.2 B
Dividend Yield 0.00%
Description Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Contact 1-1, Nihonbashi-Honcho 2-chome, Tokyo, 103-8668 https://www.takeda.com
IPO Date Jan. 5, 2010
Employees 49281
Officers Mr. Haruhiko Hirate Member of Management Board Dr. Seigo Izumo Chair of Management Board Mr. Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of R&D Global Science & Biomedical Policy Mr. Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department Mr. Christophe Weber President, Chief Executive Officer & Representative Director Mr. Milano Furuta Chief Financial Officer & Director Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Finance Mr. Yoshihiro Nakagawa Global General Counsel Norimasa Takeda Chief Accounting Officer & Corporate Controller Mr. Gabriele Ricci Chief Data & Technology Officer